Advertisement

Topics

"Products" Channels

03:08 EDT 18th August 2017 | BioPortfolio

BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.

Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html

Interested? Contact priority@bioportfolio.com

Showing Channels 1–25 of 567

Tuesday 26th April 2016

Ixekizumab (Taltz)

Ixekizumab (Taltz) is a humanised IgG4 monoclonal antibody that selectively binds with high affinity to the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.iii IL-17A is a naturally occurring cytokine that is involv...

Tuesday 4th June 2013

Vantictumab

Anti-Fzd7 (vantictumab, OMP-18R5) Vantictumab is OncoMed’s lead program in the Wnt pathway. Screened against the Frizzled 7 receptor, the antibody binds a conserved epitope on five of the Frizzled receptors. It has been shown in preclinical studi...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Preclinical studies have shown that AUT00063 has the potent...

Friday 31st May 2013

Veregen

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large n...

Eligard

Eligard® is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer. The active ingredient (leuprolide acetate) significantly reduces the level of the male sex hormone testosterone, thus suppressing testosterone-dependent ...

Wednesday 15th May 2013

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual disease monitoring has become common practice in many ha...

OncoDEEP

At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer therapies,. We always do the test OncoDEEP DX version fi...

Tuesday 14th May 2013

Eliglustat

Eliglustat acts at a level above the defective enzyme in Gaucher disease and reduces the amount of a toxic metabolite (glucosylceramide) that is the target of enzyme replacement therapy.

KYNAMRO

KYNAMRO (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total ...

Zaltrap (aflibercept)

ZALTRAP®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.

Monday 13th May 2013

Aorfix

Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anatomies with neck angulations of up to 90°. The Aor...

Monday 26th November 2012

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the entire immune system, and thus restore immunological bal...

Friday 16th November 2012

BioMimics 3D™ Stent

Veryan has developed three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The initial objective was to investigate the presence of, and effects arising from, secondary flows in a 3D...

Wednesday 24th October 2012

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across the venous arterial thromboembolic (VAT) space: The ...

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safety [2]. Macitentan has a number of potentially key benefi...

Wednesday 10th October 2012

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biopharmaceuticals. These products possess a combination of ...

Friday 7th September 2012

Dental Prosthetics

Dental Prosthetics are prosthetic implants for the mouth, and can be for cosmetic or dental reasons. The market is increasing, and technology is improving the quality of them.

Monday 3rd September 2012

RPL554

Verona’s lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor being developed as a novel treatment for chronic obstructive airways disease as COPD (chronic obstructive pulmonary disease) and asthma with bronchodilator and anti-inf...

Thursday 26th July 2012

iBioLaunch

The iBioLaunch™ platform is a  proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.  The plants are easily and reliably scaled-up in low cost, controlled growth facili...

Tuesday 24th July 2012

PATHSEEK

Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships between infections from different patients. Current platfo...

Wednesday 20th June 2012

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask the early symptoms of a variety of lung diseases before a...

Tuesday 19th June 2012

BRCA MASTR Dx

The BRCA MASTR Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers compatible with Roche’s 454 sequence...

ETS2101

ETS2101 (dexanabinol) is a synthetic cannabinoid previously studied in trauma patients. Its anti-cancer potential was identified by e-Therapeutics’ network pharmacology platform. This revealed the drug’s potential to overcome cancer cells&rsq...

Friday 4th May 2012

Lab-on-a-Chip

Lab-on-a-chip is the new trend in molecular testing, used both clinically and for research. It condenses all the processes of a conventional laboratory into a single chip which can be operated automatically. They work on the principles of micro-fluidic...

Tuesday 20th March 2012

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to: http://www.bioportfolio.com/news/article/987636/Pediculosis-Louse-Lice-Treatment.html    


Quick Search
Advertisement
 

Channels Quicklinks